© Copyright Nostre Net
The well-established global onychomycosis market is growing pervasively.
Rising prevalence of onychomycosis and per capita healthcare expenditure
worldwide are the major driving forces behind the growth of the market.
Besides, factors such as the surge in the diabetic patient population and the
increasing occurrences of peripheral artery disease (PAD) impact the market
growth positively.
Market Research Future (MRFR), in its recently published onychomycosis
marketreport, asserts that the market is estimated to rise to USD 7,912.5 MN
by 2025. MRFR also mentions that this appreciation of the market value would be
registered at 6.28% CAGR during the assessment period (2019-2025). The
availability of therapeutic medicines is blowing up the market size, providing
growth opportunities to the market players.
Get Sample Report
@https://www.marketresearchfuture.com/sample_request/1340
Drivers
& Restraints:
Some of the other major factors substantiating the market growth include
improving economic conditions worldwide that enable access to quality and
improved healthcare. Also, the changing or unhealthy lifestyle and pollution
that is led by the growing urbanization & industrialization propel the
growth of the onychomycosis treatment market globally. Additionally,
technological advancements, backed by the substantial investments made in the
R&D activities, foster the market growth excellently.
On the other hand, the lack of awareness about onychomycosis, alongside
the availability of treatments, is projected to inhibit the market growth over
the anticipated period. Also, factors such as unmet clinical needs,
side-effects associated with onychomycosis treatment medicines, drug
resistance, and complications occurring during the treatment are expected to
impede the market growth during the review period.
Global Onychomycosis Market- Segments
For enhanced understanding, themarket is segmented into four
key dynamics.
By
Type : Distal Subungual
Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual
Onychomycosis (PSO), Candida Onychomycosis, and others.
By
Treatment Type : Drug Treatment,
Topical Therapy, and others.
By
Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and others.
By
Regions : Europe, North
America, APAC, and Rest-of-the-World.
Global Onychomycosis Market- Regional analysis
North America holds the largest share in the global onychomycosis market.
The market growth attributes to the increasing number of patients suffering
from immune diseases and the presence of a huge geriatric population. Also, the
increasing prevalence of onychomycosis and peripheral artery disease acts as a
major driving force for the market growth. Besides, factors such as the
presence of key market participants, sophisticated healthcare infrastructure,
and rising per capita healthcare expenditure contribute to the regional market
growth significantly.
Europe stands second in the global onychomycosis market. The
onychomycosis market size in the region is majorly growing due to the rising
geriatric population and the increasing burden of diabetes and growing
occurrence rates of onychomycosis. Also, flourishing pharmaceutical industries
in European countries such as the UK, Germany, France, and Spain, significantly
contribute to the onychomycosis treatment market in the region.
Furthermore, factors such as the rising per capita income and strong
healthcare penetration, and the availability of advanced treatment facilities
& skilled medical professionals drive the growth of the regional market at
a large scale. Also, the government support for research & development
plays a major role in the development of European onychomycosis markets.
Asia Pacific has emerged as a rapidly progressing market for
onychomycosis due to the rising prevalence of various skin infections. Markets
in China and India backed by the vast population and the availability of
low-cost medications to treat Onychomycosis treatment foster the market growth
in the region. Moreover, the rapidly growing healthcare sectors, coupled with
the large unmet needs, provide impetus to the market growth.
Global Onychomycosis Market- Competitive Analysis
Highly competitive, the global onychomycosis market appears to be
fragmented due to the presence of a large number of players. The increase of
spurious and counterfeit medicines has opened doors for new drug development
and opportunities for a new market leader. To gain a larger competitive advantage,
these players incorporate strategies such as mergers & acquisitions,
expansions, collaborations, and product/technology launch.
Major Players:
Some of the eminent leaders in the global Onychomycosis market include
Pfizer, Inc. (the US), Novartis AG (Switzerland), Galderma Laboratories
(Switzerland), Moberg Pharma AB (Sweden), Bausch Health Sciences (Canada), Dr.
Reddy's Laboratories Ltd (India), Merz Pharma (Germany), Medimetriks
Pharmaceuticals, Inc. (US), Kaken Pharmaceutical Co., Ltd. (Japan), GlaxoSmithKline
plc (UK), Taro Pharmaceuticals Industries Ltd. (Israel), and Johnson &
Johnson Services, Inc. (US), among others.
Industry/Innovations/Related News:
April 20, 2020 ---- Novan, Inc.
(the US), a clinical-stage biotechnology company, announced its collaboration
with a US-based full-service investment bank H.C. Wainwright & Co., LLC.
Novan is focused on leveraging nitric oxide's natural antiviral and
immunomodulatory mechanisms of action to treat a number of contagious skin
infection and oncovirus-mediated diseases. It is developing a topical antiviral
gel SB206 for the treatment of viral skin infections caused by the
molluscipoxvirus.
H. C. Wainwright & Co. provides end to end services like investment
banking, equity research, sales & trading as well corporate access, and
strategic advisory services. The partnership would aid in exploring and
evaluating a range of strategic and financial alternatives intended to maximize
the Company's shareholder value.
Novan's clinical and preclinical data, technology platform, and market
potential also includes its medicine SB208, which is indented for the treatment
of tinea pedis and onychomycosis. Currently, SB208 is positioned to initiate a
Phase 2 trial in onychomycosis following positive results in a Phase 2 study.
Access full report @ https://www.marketresearchfuture.com/reports/onychomycosis-market-1340
Get More Related
Report
About US:
Market Research Future (MRFR), enable
customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of
Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
The Wall